Weight Loss

Following a US FDA warning over a rare vision-loss condition, specialists say the absolute risk remains low, while the metabolic and cardiovascular benefits of GLP-1 drugs are substantial

Updated On: 12 Nov 2026 | 10:40 PM IST

Popular weight loss drugs including Ozempic and Wegovy will carry a new warning about a possible rare side effect that can sometimes lead to permanent vision loss, US health regulators announced Monday. The Food and Drug Administration said the risk will be added to the labeling of all GLP-1 drugs, the blockbuster medications used to treat obesity, diabetes and several other medical conditions. The class includes a dozen injectable or pill-based drugs, including widely used brands like Zepbound and Mounjaro. The eye condition, known as non-arteritic anterior ischemic optic neuropathy, can cause significant vision loss. The problem, which has been reported with all GLP-1 drugs, is caused by decreased blood flow to the optic nerve, although the underlying cause isn't understood, the FDA said. FDA scientists began looking into the problem after the publication of a 2024 medical paper tying the condition to certain patients taking semaglutide, the active drug in Eli Lilly's Ozempic. An

Updated On: 10 Nov 2026 | 8:47 AM IST

Brazil has 16.6 million adults aged between 20 and 79 living with diabetes, and ranks sixth globally in terms of the number of adults living with diabetes

Updated On: 05 Nov 2026 | 11:50 AM IST

Weight-loss drugs have become major businesses ‌for large pharmaceutical companies. The US is among a handful of countries that allow direct-to-consumer advertising of prescription medicines

Updated On: 27 Oct 2026 | 8:36 AM IST

The addressable ​market could grow at an annual rate of 15% through 2035, JP Morgan ‌analysts led by Yang Huang said in a note on Friday, given the countries' large diabetes and obesity burdens

Updated On: 23 Oct 2026 | 3:54 PM IST

L'Oreal is testing products on users of weight-loss drugs, as beauty companies explore treatments for skin changes associated with rapid weight loss

Updated On: 23 Oct 2026 | 9:51 AM IST

The fast-food giant is testing chicken and burger bowls, snack wraps and egg bites as some consumers on GLP-1 drugs seek smaller portions and more protein

Updated On: 24 Sep 2026 | 7:49 AM IST

Weight-loss drugs are changing what consumers buy, putting protein, fibre, smaller portions and nutrient density at the centre of the next packaged-food opportunity

Updated On: 24 Aug 2026 | 1:44 PM IST

The rapid adoption of drugs made by Novo Nordisk and Eli Lilly has fuelled investor concerns that appetite-suppressing medicines could permanently reduce demand for packaged foods, snacks and beverage

Updated On: 17 Aug 2026 | 11:49 AM IST

South Korea's L&C Bio plans an injectable skin booster from donated human fat to restore facial volume, targeting cosmetic concerns linked to GLP-1 weight-loss drugs

Updated On: 06 Aug 2026 | 11:10 PM IST

Lilly on Friday denied any wrongdoing, saying it stood by its advertising and would vigorously defend itself. Novo and Lilly are battling for dominance in the obesity drug market

Updated On: 25 Jul 2026 | 12:26 AM IST

The expanding domestic market for semaglutide-based weight-loss drugs is expected to help cushion weaker US sales for Cipla and Dr Reddy's after the loss of Revlimid exclusivity

Updated On: 20 Jul 2026 | 10:26 AM IST

GLP-1 weight-loss drugs are changing more than just waistlines, they're changing how food tastes. And that's forcing food giant Nestlé to rethink its products.

Updated On: 15 Jul 2026 | 12:40 PM IST
Icon Youtube

Nestle's chefs are working with people taking GLP-1 drugs to develop new flavour combinations, including potentially using more spices and pepper to compensate for dulled taste perception

Updated On: 08 Jul 2026 | 1:36 PM IST

Demand for GLP-1 drugs such as semaglutide is exposing capacity gaps across peptide APIs, sterile fill-finish facilities, injector devices and glass cartridges

Updated On: 28 Jun 2026 | 10:38 PM IST

After a near fourfold expansion driven by generic semaglutide launches, India's GLP-1 market is showing signs of moderation as patient onboarding growth slows

Updated On: 08 Jun 2026 | 7:18 PM IST

Patients in France are currently paying around €300 ​per month on average for the drugs, she said, without indicating how many people currently follow such treatments

Updated On: 28 May 2026 | 6:46 PM IST

Heavy sweating may feel like proof of an effective workout, but experts say fat loss depends on far more than perspiration alone

Updated On: 15 May 2026 | 3:55 PM IST

Mounjaro generated $8.7 billion for Lilly in the first quarter of 2026, outperforming Merck's Keytruda, which posted sales of $7.9 billion

Updated On: 07 May 2026 | 8:05 AM IST

Authorities have unearthed a racket involving the manufacturing and sale of "fake" Mounjaro (tirzepatide) injections and arrested two persons here in this connection, an official said on Monday. A nationwide alert has been issued to detect the counterfeit injections and an investigation is underway to unravel the entire network, including all those involved in this racket, Drug Control Officer Amandeep Chauhan said. He said a Health Department team raided a residential society in Sector 62 on Monday and arrested two people, including the key accused. The accused were importing raw drugs from China and manufacturing counterfeit injections of Mounjaro. The entire racket was being run from a flat in the society. The accused supplied these illegal injections through the B2B portal Indiamart, the officer alleged. Mounjarois a weekly injectable medication for type 2 diabetesthat significantly improves blood sugar control and aids weight loss. "We received information about a fake inject

Updated On: 21 Apr 2026 | 9:22 AM IST